Rhenman & Partners Asset Management Ab Regeneron Pharmaceuticals, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 39,000 shares of REGN stock, worth $27.9 Million. This represents 3.41% of its overall portfolio holdings.

Number of Shares

39,000

Previous 32,000 21.88%

Holding current value

$27.9 Million

Previous $33.6 Million 21.9%

% of portfolio

3.41%

Previous 3.32%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1024.09 - $1201.76 $7.17 Million - $8.41 Million	7,000 Added 21.88%	39,000 $41 Million
Q2 2024 Aug 13, 2024	SELL	$883.2 - $1071.19 $2.03 Million - $2.46 Million	-2,300 Reduced 6.71%	32,000 $33.6 Million
Q1 2024 May 14, 2024	SELL	$902.69 - $993.35 $4.24 Million - $4.67 Million	-4,700 Reduced 12.05%	34,300 $33 Million
Q4 2023 Feb 13, 2024	SELL	$775.18 - $881.7 $775,180 - $881,700	-1,000 Reduced 2.5%	39,000 $34.3 Million
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $3.46 Million - $4.22 Million	5,000 Added 14.29%	40,000 $32.9 Million
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $350,015 - $415,175	-500 Reduced 1.41%	35,000 $25.1 Million
Q1 2023 May 11, 2023	SELL	$680.49 - $826.97 $1.02 Million - $1.24 Million	-1,500 Reduced 4.05%	35,500 $29.2 Million
Q4 2022 Feb 13, 2023	BUY	$705.89 - $766.39 $3.53 Million - $3.83 Million	5,000 Added 15.63%	37,000 $26.7 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $10.3 Million - $13 Million	18,000 Added 128.57%	32,000 $24 Million
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $7.95 Million - $10.7 Million	-14,500 Reduced 50.88%	14,000 $8.28 Million
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $17 Million - $19.9 Million	28,500 New	28,500 $19.9 Million
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $14.4 Million - $17 Million	-25,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$472.8 - $558.54 $2.36 Million - $2.79 Million	5,000 Added 25.0%	25,000 $14 Million
Q1 2021 May 14, 2021	SELL	$446.73 - $548.2 $8.93 Million - $11 Million	-20,000 Reduced 50.0%	20,000 $9.46 Million
Q4 2020 Jan 19, 2021	BUY	$478.3 - $607.98 $8.37 Million - $10.6 Million	17,500 Added 77.78%	40,000 $19.3 Million
Q3 2020 Oct 13, 2020	BUY	$544.75 - $658.21 $5.45 Million - $6.58 Million	10,000 Added 80.0%	22,500 $12.6 Million
Q2 2020 Jul 16, 2020	BUY	$493.32 - $643.92 $6.17 Million - $8.05 Million	12,500 New	12,500 $7.8 Million
Q1 2020 Apr 16, 2020	SELL	$336.18 - $494.43 $9.08 Million - $13.3 Million	-27,000 Closed	0 $0
Q4 2019 Jan 17, 2020	SELL	$274.13 - $376.51 $4.94 Million - $6.79 Million	-18,031 Reduced 40.04%	27,000 $10.1 Million
Q3 2019 Oct 16, 2019	BUY	$273.46 - $318.39 $4,648 - $5,412	17 Added 0.04%	45,031 $12.5 Million
Q2 2019 Jul 22, 2019	BUY	$299.6 - $414.82 $8.69 Million - $12 Million	29,014 Added 181.34%	45,014 $14.1 Million
Q1 2019 Apr 11, 2019	SELL	$372.08 - $439.57 $372,080 - $439,570	-1,000 Reduced 5.88%	16,000 $6.57 Million
Q2 2018 Jul 20, 2018	SELL	$284.6 - $344.99 $4.84 Million - $5.86 Million	-17,000 Reduced 50.0%	17,000 $5.87 Million
Q1 2018 Apr 11, 2018	BUY	$315.82 - $393.78 $898,823 - $1.12 Million	2,846 Added 9.14%	34,000 $11.7 Million
Q4 2017 Jan 19, 2018	BUY	$358.63 - $469.95 $3.28 Million - $4.3 Million	9,154 Added 41.61%	31,154 $11.7 Million
Q3 2017 Oct 13, 2017	BUY	$431.38 - $504.0 $9.49 Million - $11.1 Million	22,000	22,000 $9.84 Million

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.6B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Regeneron Pharmaceuticals, Inc. Transaction History